AAD 2026: 7 Late-Breaking Data Updates to Know in Dermatology

The 2026 American Academy of Dermatology Annual Meeting, held March 27–31 in Denver, Colorado, delivered one of the most consequential late-breaking programs in recent memory—one that may look, in retrospect, like a turning point for oral therapy in immune-mediated skin disease. Plaque psoriasis alone commanded multiple pivotal readouts, with the phase 3 LATITUDE and ONWARD programs for zasocitinib and envudeucitinib respectively positioning a second wave of TYK2 inhibitors as potential biologic-level competitors in a once oral-skeptical space. The message from both datasets was strikingly consistent: high skin clearance rates, rapid onset, durable responses, and safety profiles that don't carry the warnings associated with broader JAK inhibition.